+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
ID07910708

Evaluating GN001 as a Treatment for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia Using Dose Escalation

Led by Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital · Updated on 2026-11-02

42

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating GN001, an investigational lentiviral vector-based treatment that aims to generate CD19-targeted CAR T cells inside the body. This study involves adults aged 18 to 75 years with CD19-positive relapsed or refractory B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia. The main goal is to assess the safety and tolerability of GN001 at various doses while also monitoring antitumor activity and biological responses. Participants receive a single intravenous infusion of GN001 at different dose levels, starting from 1 x 108 TU up to 1 x 109 TU. The study uses a dose-escalation design beginning with accelerated titration and transitioning to a 33 design based on safety criteria. Dose expansion may occur after reviewing safety data. The treatment is administered sequentially across different cohorts. During the study, participants are monitored for dose-limiting toxicities for 28 days after infusion. Researchers will evaluate the expansion and persistence of the CAR T cells and their biological effects. Long-term safety follow-up is planned to continue monitoring participants. The total participation duration extends until the study completion in August 2029.

CONDITIONS

Brief Title

GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here